Schistosoma haematobium infections (urogenital schistosomiasis) Infections and Infestations Schistosoma haematobium, urogenital schistosomiasis, bilharziasis
Conditions
Interventions
The S. haematobium prevalence will be determined annually (2018, 2019, 2020, 2021) in cross-sectional surveys conducted in schools and communities of the study area.
Mass drug administration with pra
Sponsors
Swiss Tropical and Public Health Institute
Eligibility
Sex/Gender
All
Age
13 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Children attending the selected nurseries and schools 2. Adolescents or adults aged =13 years from the selected shehias, including pregnant women, only one adolescent and/or adult per household eligible 3. Submitted informed consent form (ICF) signed by a parent or legal guardian in case of participating children and adolescents, or signed by the participant in case of participating adults 4. Able to provide one urine sample with sufficient volume to perform diagnostic tests
Exclusion criteria
Exclusion criteria: Does not meet inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measure as of 27/07/2020: Number of S. haematobium infected individuals detected by the urine filtration method (detecting S. haematobium eggs in 10 ml urine) and reagent strip method (Hemastix; detecting microhaematuria in urine) applied on a single urine sample per participant in each annual cross-sectional survey in 2018, 2019, 2020, and 2021 Previous primary outcome measure: Number of S. haematobium infected individuals detected by the urine filtration method (detecting S. haematobium eggs in 10 ml urine) and reagent strip method (Hemastix; detecting microhaematuria in urine) applied on a single urine sample per participant in each cross-sectional survey at 0, 1, 2, and 3 years | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 27/07/2020: 1. Impact of mass drug administration (MDA) with praziquantel (40 mg/kg) over time measured in 2018, 2019, 2020, and 2021 during the annual cross-sectional school-based and community-based surveys using: 1.1. S. haematobium prevalence measured by urine filtration (S. haematobium egg absence/presence in 10 ml urine) and measured by reagent strips to assess microhaematuria absence/presence 1.2. S. haematobium infection intensity measured by urine filtration (S. haematobium egg counts in 10 ml urine) 2. Age-prevalence distribution by age and stratified by sex, measured by urine filtration and reagent strips, sex and age will be recorded on enrolment and in 2018, 2019, 2020, and 2021 during the annual cross-sectional school-based and community-based surveys 3. Treatment coverage and compliance of MDA with praziquantel (40 mg/kg) preceding the cross-sectional survey, determined with questionnaires in annual cross-sectional surveys (coverage is defined as the percentage of those queried receiving praziquantel tablets during MDA, and compliance is defined as the percentage of those queried swallowing praziquantel tablets in the dose supplied during MDA) in 2018, 2019, 2020, and 2021 4. Risk factors for S. haematobium infection determined with questionnaires (query the use of natural open freshwater bodies for washing, bathing and household chores, travel, location of residence and demographic factors) during annual cross-sectional surveys in 2018, 2019, 2020, and 2021 Previous secondary outcome measures: 1. Impact of mass drug administration (MDA) with praziquantel (40 mg/kg) over time measured at 0, 1, 2 and 3 years during the annual cross-sectional school-based and community-based surveys using: 1.1. S. haematobium prevalence measured by urine filtration (S. haematobium egg absence/presence in 10 ml urine) and measured by reagent strips to assess microhaematuria absence/presence 1.2. S. haematobium infection intens | — |
Countries
Tanzania
Outcome results
None listed